Circadian antihypertensive profile of carvedilol (BM 14190).
Carvedilol (BM 14190) is a new potent and well-tolerated beta-adrenoceptor antagonist with vasodilating properties. Acute clinical studies have confirmed its efficacy as an antihypertensive agent. The present double-blind, randomized, metoprolol-controlled, long-term study reports the therapeutic results of carvedilol in essential hypertensive patients. Compared with placebo, carvedilol significantly reduces blood pressure after oral administration of 50 mg on a single and twice daily regimen. The antihypertensive effect was acute in onset, comparable in supine and standing position, and exercise-induced hypertension and tachycardia were significantly reduced. Indirect automatic 24 h blood pressure monitoring reliably confirmed clinic blood pressure and demonstrated a good antihypertensive effect of carvedilol after a single oral administration throughout daily activities and sleeping periods.
Meyer-Sabellek
W
W
Department of Internal Medicine, Klinikum Steglitz, Freie Universität, Berlin, F.R.G.
Schulte
K L
KL
Distler
A
A
Gotzen
R
R
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure; D001835:Body Weight; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D002940:Circadian Rhythm; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008790:Metoprolol / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D005082:Physical Exertion; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol